Osteoporosis Drug Market

Osteoporosis Drugs Market (By Drug Class Bisphosphonates, Calcitonin, RANK Ligand Inhibitors, Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators (SERMs), Others Estrogen therapy and vitamin D and Calcium) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends & Forecast 2014 - 2020

  • Rep Id : TMRGL133
  • Published On : Aug 2014
  • No. of Pages : 98
  • Category : Pharmaceutical

 
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Sources
               1.3.1.1 Secondary Research
               1.3.1.2 Primary Research
       1.3.2 Assumptions
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Osteoporosis Drugs Market (2013 & 2020)
2.2 Global Osteoporosis Drugs Market, by Drug Class, 2013 (USD Million)
2.3 Competitive Analysis: Global Osteoporosis Drugs Market, By Geography, 2013 & 2020 (Value %)
 
Chapter 3 Disease Overview: Osteoporosis
3.1 Introduction
3.2 Classification
3.3 Causes
3.4 Signs and symptoms
       3.4.1 Fractures
       3.4.2 Falls risk
3.5 Risk Factors
       3.5.1 Uncontrollable factors
       3.5.2 Controllable and changeable factors
       3.5.3 Medical diseases propelling the disease
       3.5.4 Medicines propelling the osteoporosis
3.6 Diagnostics Tests
       3.6.1 Dual-Energy X-Ray Test
               3.6.1.1 Diagnostic Guidelines by World Health Organization:
       3.6.2 Biomarkers
       3.6.3 Conventional radiography tests
3.7 Disease Management
       3.7.1 Lifestyle management
       3.7.2 Nutrition Emphasis
       3.7.3 Medicines
3.8 Conclusion
 
Chapter 4 Market Overview
4.1 Overview
4.2 Market Drivers
       4.2.1 Rising prevalence of osteoporosis and aging population boosts the growth of the global market
                4.2.1.1 Incidence of osteoporosis  based on age (in women), 2010
                4.2.1.2 Incidence of osteoporosis  based on age (in men), 2010
       4.2.2 Introduction of new drug classes with higher efficiency to overcome the threat of generics and side effects propels market growth
4.3 Market Restraints
       4.3.1 Stringent regulatory norms and Phase IV investigations by regulatory authorities hamper the osteoporosis drugs market
       4.3.2 Patent expiry of blockbuster drugs and dynamic changes in pricing due to generics restrain market growth
4.4 Market Opportunities
       4.4.1 Focus on R&D for development of new drugs and classes can help in accentuating the market growth
4.5 Porter’s Five Force Analysis of the Global Osteoporosis Drugs Market
       4.5.1 Bargaining power of suppliers
       4.5.2 Bargaining power of buyers
       4.5.3 Threat of new entrants
       4.5.4 Threat of substitutes
       4.5.5 Competitive rivalry
4.6 Event Impact Analysis: Global Osteoporosis Drugs Market
       4.6.1 Impact of positive events on the osteoporosis drugs market
       4.6.2 Impact of negative events on the osteoporosis drugs market
4.7 Value Chain Analysis
       4.7.1 Value Chain Analysis for Osteoporosis Drugs Market
4.8 Market Share Analysis
       4.8.1 Market Share Analysis, Osteoporosis Drugs Market, 2012 (Value %)
4.9 Market Attractiveness Analysis: Global Osteoporosis Drugs Market, by Geography
 
Chapter 5 Global Osteoporosis Drugs Market Revenue, by Drugs Class 2012 – 2020 (USD Million)
5.1 Overview
       5.1.1 Global Osteoporosis Drugs Market Revenue, by Drug Class, 2012 – 2020 (USD Million)
5.2 Bisphosphonates
       5.2.1 Global Bisphosphonates Market Revenue, 2012 – 2020 (USD Million)
5.3 Parathyroid Hormone Therapy (PTH) Drugs
      5.3.1 Global Parathyroid Hormone Therapy (PTH) Market Revenue, 2012 – 2020(USD Million)
5.4 Selective Estrogen Receptor Modulators (SERMs)
       5.4.1 Global Selective Estrogen Receptor Modulators (SERMs) Market Revenue, 2012 – 2020 (USD Million)
5.5 RANK Ligand Inhibitors (Denosumab)
       5.5.1 Global RANK Ligand Inhibitors Market Revenue, 2012 – 2020 (USD Million)
5.6 Calcitonin
       5.6.1 Global Calcitonin Market Revenue, 2012 – 2020 (USD Million)5.7 Others
5.7 Global Others Market Revenue, 2012 – 2020 (USD Million)
5.8 Pipeline Analysis
       5.8.1 Odanacatib
                5.8.1.1 Global Odanacatib Market Revenue, 2016 – 2020 (USD Million)
       5.8.2 Romosozumab
                5.8.2.1 Global Romosozumab Market Revenue, 2017 – 2020 (USD Million)
 
Chapter 6 Global Osteoporosis Dugs Market Revenue, by Geography, 2012 – 2020 (USD Million)
6.1 Overview
       6.1.1 Global Osteoporosis Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million)
6.2 North America
       6.2.1 North America Osteoporosis Drugs Market Revenue, 2012 – 2020 (USD Million)
6.3 Europe
       6.3.1 Europe Osteoporosis Drugs Market Revenue, 2012 – 2020 (USD Million)
6.4 Asia-Pacific
       6.4.1 Asia-Pacific Osteoporosis Drugs Market Revenue, 2012 – 2020 (USD Million)
6.5 Rest of the World (RoW)
       6.5.1 Rest of the World (RoW) Osteoporosis Drugs Market Revenue, 2012 – 2020 (USD Million)
 
Chapter 7 Recommendations
7.1 Focus on R&D and emphasis on development of formulations and molecules from new drug classes
7.2 Emphasis on spreading awareness about the disease as well as marketing and promotional campaigns
7.3 Focus on Emerging Markets and Asia-Pacific (EMAP) region
7.4 Mergers, Acquisitions and Collaborations
 
Chapter 8 Company Profiles
8.1 Actavis plc
       8.1.1 Company Overview
       8.1.2 Financial Overview
       8.1.3 Product Portfolio
       8.1.4 Business Strategies
       8.1.5 Recent Developments
8.2 Amgen, Inc.
       8.2.1 Company Overview
       8.2.2 Financial Overview
       8.2.3 Product Portfolio
       8.2.4 Business Strategies
       8.2.5 Recent Developments
8.3 Eli Lilly and Company
       8.3.1 Company Overview
       8.3.2 Financial Overview
       8.3.3 Product Portfolio
       8.3.4 Business Strategies
       8.3.5 Recent Developments
8.4 F. Hoffmann-La Roche Ltd.
       8.4.1 Company Overview
       8.4.2 Financial Overview
       8.4.3 Product Portfolio
       8.4.4 Business Strategies
       8.4.5 Recent Developments
8.5 Merck & Co., Inc.
       8.5.1 Company overview
       8.5.2 Financial overview
       8.5.3 Product portfolio
       8.5.4 Business Strategies
       8.5.5 Recent Developments
8.6 Novartis International AG
       8.6.1 Company Overview
       8.6.2 Financial Overview
       8.6.3 Product Portfolio
       8.6.4 Business Strategies
       8.6.5 Recent Developments
8.7 Novo Nordisk A/S
       8.7.1 Company Overview
       8.7.2 Financial Overview
       8.7.3 Product Portfolio
       8.7.4 Business Strategies
       8.7.5 Recent Developments
8.8 Pfizer, Inc.
       8.8.1 Company Overview
       8.8.2 Financial Overview
       8.8.3 Product Portfolio
       8.8.4 Business Strategies
       8.8.5 Recent Developments
8.9 Teva Pharmaceutical Industries Ltd.
       8.9.1 Company Overview
       8.9.2 Financial Overview
       8.9.3 Product Portfolio
       8.9.4 Business Strategies
       8.9.5 Recent Developments

List of Tables
 
TABLE 1 Market Snapshot: Global Osteoporosis Drugs Market (2013 and 2020)
TABLE 2 Global Osteoporosis Drugs Market Revenue, by Drug Class, 2012 – 2020 (USD Million)
TABLE 3 Global Osteoporosis Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million)

List of Figures
 
FIG. 1 Market Segmentation: Osteoporosis Drugs Market
FIG. 2 Global Osteoporosis Drugs Market, by Drug Class, 2013 (USD Million)
FIG. 3 Comparative Analysis: Global Osteoporosis Drugs Market Revenue, by Geography, 2013 & 2020 (Value %)
FIG. 4 Incidence of osteoporosis based on age (in women), 2010
FIG. 5 Incidence of osteoporosis based on age (in men), 2010
FIG. 6 Porter’s Five Force Analysis: Global Osteoporosis Drugs Market
FIG. 7 Value Chain Analysis for Osteoporosis Drugs Market
FIG. 8 Market Share Analysis, Global Osteoporosis Drugs Market, 2013 (Value %)
FIG. 9 Market Attractiveness Analysis: Global Osteoporosis Drugs Market, by Geography
FIG. 10 Global Bisphosphonates Market Revenue, 2012 – 2020 (USD Million)
FIG. 11 Global Parathyroid Hormone Therapy (PTH) Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 Global Selective Estrogen Receptor Modulators (SERMs) Market Revenue, 2012 – 2020 (USD Million)
FIG. 13 Global RANK Ligand Inhibitors Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Global Calcitonin Market Revenue, 2012 – 2020 (USD Million)
FIG. 15 Global Others Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 Odanacatib (MK-0822) Market Revenue, 2016 – 2020 (USD Million)
FIG. 17 Romosozumab Market Revenue, 2017 – 2020 (USD Million)
FIG. 18 North America Osteoporosis Drugs Market Revenue, 2012 – 2020 (USD Million)
FIG. 19 Europe Osteoporosis Drugs Market Revenue, 2012 – 2020 (USD Million)
FIG. 20 Asia-Pacific Osteoporosis Drugs Market Revenue, 2012 – 2020 (USD Million)
FIG. 21 Rest of the World (RoW) Osteoporosis Drugs Market Revenue, 2012 – 2020 (USD Million)
FIG. 22 Actavis plc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 23 Amgen, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 24 Eli Lilly and Company: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 25 F. Hoffmann-La Roche Ltd.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 26 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 27 Novartis International AG: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 28 Novo Nordisk A/S.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 29 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 30 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2011 – 2013 (USD Million)